Sudeep Pharma Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹163Cr
- +9.4% YoY
- +30.4% QoQ
- Net profit
- ₹47Cr
- −4.1% YoY
- +51.6% QoQ
- Margin
- 34%
- −9 pp YoY
- −1 pp QoQ
Guidance rank: #24 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
FY '26 growth expected at approximately 26%, sustained for the full year. Sudeep Pharma expects to sustain the 26% growth achieved in H1 FY26 for the full year FY26 and beyond, driven by normalization of U.S.
From Sudeep Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 growth expected at approximately 26%, sustained for the full year.
- Significant growth anticipated in Q3 FY '26, especially in the US market, post-tariff clarity.
- NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area.
- NSS capacity utilization currently ~35%, with plans to scale volumes notably by FY '27.
- New Greenfield facility (51,200 metric tons capacity) expected commissioning Q4 FY '26; first meaningful production from this site expected in H2 FY '27 and predominantly FY '28.
- Current overall manufacturing utilization near 50%, expected to increase with new capacity and approvals over next 2-3 years.
2 more points from Sudeep Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sudeep Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Acquired a 20-acre land in Dahej for new manufacturing facility.
- Phase one capex for Dahej site: ~INR 220 crores (includes land and development) for 25,000 tons capacity.
- Infrastructure being built to support phase two, doubling capacity to 50,000 tons.
- Long-term goal to scale plant to 100,000 tons for battery-grade iron phosphate.
- Total expected capex to reach ~INR 500 crores over next few years.
- Existing pilot plant producing 200 kgs/day; samples supplied to 36+ customers.
- Capacity enhancement planned on existing food grade iron phosphate line to meet early demand before Dahej plant operational.
- Greenfield capex of INR 150 crores for 51,200 MT capacity, with INR 120 crores spent by Sept '25; balance INR 20-30 crores to be spent by March '26.
2 more points from Sudeep Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudeep Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company anticipates a strong Q3 FY26 due to delayed order book recognition in Q2, especially from the US market impacted by tariff uncertainties.
- NSS, acquired in May 2025, has a significant project pipeline in Europe and global markets to expand its infant and clinical nutrition offerings.
- NSS is currently operating at approximately 35% capacity utilization, with plans to scale up through leveraging Sudeep Pharma’s global customer base.
- Campaign orders for large pharma and nutrition companies contribute significantly but are irregular, causing quarterly fluctuations in order volumes.
2 more points from Sudeep Pharma Ltd's call on order book
Create a free account to keep reading this call
Sudeep Pharma Ltd — Quarterly revenue & net profit
Sudeep Pharma Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 163 | 149 | +9.4% | 125 | +30.4% |
| Operating profit (EBITDA) | 55 | 63 | -12.7% | 44 | +25% |
| Operating margin | 34% | 43% | -9 pp | 35% | -1 pp |
| Profit before tax | 60 | 62 | -3.2% | 44 | +36.4% |
| Net profit (PAT) | 47 | 49 | -4.1% | 31 | +51.6% |
| EPS (₹) | 4.71 | 5.80 | -18.8% | 3.17 | +48.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹197 Cr, net profit ₹52 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudeep Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sudeep Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sudeep Pharma Ltd Q2 FY26 results?
FY '26 growth expected at approximately 26%, sustained for the full year. Sudeep Pharma expects to sustain the 26% growth achieved in H1 FY26 for the full year FY26 and beyond, driven by normalization of U.S.
What is Sudeep Pharma Ltd share price analysis?
Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 59.3 with a market cap of ₹10,831 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudeep Pharma Ltd planning capital expenditure?
Acquired a 20-acre land in Dahej for new manufacturing facility.
Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
